malignant pleural effusion

A malignant pleural effusion is a buildup of fluid in the space between the lung and the chest wall, caused directly or indirectly by cancer. It affects roughly 150,000 people a year in the United States alone and signals advanced disease, typically stage IV. The fluid accumulates because tumors disrupt the normal balance of fluid production and drainage in the pleural space, and the condition almost always causes progressive breathlessness that erodes quality of life. While a malignant pleural effusion cannot be cured in the traditional sense, a growing toolkit of interventions can control symptoms, reduce time in hospital, and help people spend more of their remaining months at home.

How the Fluid Builds Up

The pleural space normally contains only a thin film of fluid that lets the lung slide smoothly against the chest wall during breathing. Cancer changes this in two ways at once. Tumor deposits on the pleural membranes or nearby blood vessels make those surfaces leaky, so more fluid seeps in than usual. At the same time, cancer cells and the inflammation they provoke can clog or compress the lymphatic channels that normally drain excess fluid out of the space. The combination of increased inflow and reduced outflow is what researchers believe drives most malignant pleural effusions.¹ Lung cancer and breast cancer are the two most common causes, but almost any cancer that has spread can trigger it, including lymphomas, ovarian cancer, and mesothelioma.

Why It Makes You So Breathless

You might assume that a large effusion causes shortness of breath simply by compressing the lung and preventing it from expanding. The reality is more nuanced. Current evidence points to the diaphragm as the main culprit. When fluid fills the pleural space, it pushes the diaphragm downward and flattens it. A flattened diaphragm cannot generate its normal force during contraction because the muscle fibers are stretched beyond their optimal working length. This disruption in what physiologists call the length-tension relationship of the respiratory muscles appears to be the primary driver of breathlessness in pleural effusion.²

This mechanism also explains something that puzzles many patients: after a drainage procedure, you can feel dramatically better even though imaging shows that the lung has not fully re-expanded. The relief comes not from getting more lung inflated but from allowing the diaphragm to return toward its natural dome shape, restoring its mechanical advantage. Lung re-expansion, surprisingly, does not play a major role in improving the sensation of breathlessness.³

Getting the Diagnosis Right

When a pleural effusion is discovered on imaging, the first diagnostic step is usually a thoracentesis: a needle is inserted into the pleural space to draw off fluid for analysis. If cancer cells are found in that fluid sample, the diagnosis is confirmed. However, fluid cytology misses a substantial number of cases. A systematic review and meta-analysis covering more than 6,000 patients found that the overall sensitivity of pleural fluid cytology for detecting malignancy was about 58%, meaning it catches roughly six out of every ten malignant effusions on the first attempt.⁴

That average hides a wide spread depending on the type of cancer. Cytology performs best for adenocarcinomas: lung adenocarcinoma was detected in about 84% of cases, and ovarian cancer in about 85%. It performs poorly for squamous cell lung cancer (around 24%) and mesothelioma (around 29%).⁵ For mesothelioma and blood cancers, a pleural biopsy is significantly more accurate than cytology alone.⁶

Biopsy Options When Cytology Falls Short

If the fluid sample is negative but suspicion for cancer remains, the next step is obtaining tissue from the pleura itself. There are broadly two routes: image-guided needle biopsy (using ultrasound or CT to steer the needle into a suspicious area) and medical thoracoscopy (inserting a small camera through the chest wall to visualize the pleural surface directly and take targeted biopsies).

A large network meta-analysis of 64 studies and nearly 8,750 patients found that rigid medical thoracoscopy had the highest diagnostic yield at about 95%, followed closely by cryobiopsy and semi-rigid thoracoscopy at around 92–93%. Ultrasound-guided biopsy reached a similar range, and no statistically significant difference was found between image-guided biopsy and rigid thoracoscopy.⁷ A smaller head-to-head study found thoracoscopy detected 95% of cases versus 85% for ultrasound-guided needle biopsy, with no significant statistical difference between the two.⁸ In practice, the choice often comes down to local availability and patient fitness. Thoracoscopy requires sedation and a procedure suite; image-guided biopsy can be done more quickly and with lighter sedation in settings where thoracoscopy is not available.

Predicting How Long Someone Has

Prognosis varies enormously. Some people with malignant pleural effusions from slow-growing cancers live for years; others with aggressive disease survive only weeks. Clinicians have developed scoring systems to help estimate survival, and the two most studied are the LENT score (which factors in fluid characteristics, tumor type, and performance status) and the PROMISE score (which uses clinical and blood-test variables). An external validation study found that both scores predicted survival at three, six, and twelve months reasonably well, with a measure of discrimination hovering around 0.8 at each of those time points.⁹ However, pinpointing a median survival number for any individual patient remained imprecise.

These scores matter for treatment decisions. A person expected to survive only a few weeks might benefit most from a simple, repeatable drainage approach rather than a procedure requiring recovery time. Someone with months ahead might benefit from a more definitive intervention aimed at preventing the fluid from returning.

The Two Main Treatment Strategies

For most patients with a symptomatic malignant pleural effusion, the goal is to stop fluid from reaccumulating. Two approaches dominate: chemical pleurodesis and indwelling pleural catheters. Both work, and neither has proven clearly superior for symptom relief or quality of life.

Chemical Pleurodesis

Pleurodesis involves instilling a sclerosing agent, most commonly talc, into the pleural space to trigger an inflammatory reaction that seals the two pleural surfaces together. Once the surfaces are fused, there is no space for fluid to collect. Talc can be delivered as a slurry through a chest tube or sprayed as a powder (called poudrage) during thoracoscopy. Pleurodesis has been used for decades and can achieve high success rates.¹⁰ The main drawbacks are that it typically requires a hospital stay of several days, the lung must be able to expand enough to make contact with the chest wall (otherwise the surfaces cannot fuse), and the procedure can cause chest pain and fever in the short term. Studies have shown that pleurodesis improves respiratory symptoms, physical function, and general health in quality-of-life assessments afterward.¹¹

Indwelling Pleural Catheters

An indwelling pleural catheter (IPC) is a thin silicone tube that is tunneled under the skin and left in place long-term. You or a caregiver can connect a vacuum bottle to the external end and drain fluid at home, usually every one to three days. The big advantage is that it requires minimal time in hospital and puts you in control of your own symptom management. In a randomized trial comparing IPCs with talc pleurodesis, the catheter group spent fewer total days in hospital (a median of ten versus twelve) and needed far fewer repeat invasive drainage procedures, with only about 4% requiring further procedures on the same side compared with roughly 23% in the pleurodesis group.¹² Breathlessness and quality-of-life improvements were similar between the two groups.

An added benefit of IPCs is that a substantial proportion of patients experience spontaneous pleurodesis: the catheter’s presence gradually irritates the pleural surfaces into fusing on their own, allowing the catheter to be removed. In one prospective study, spontaneous pleurodesis occurred in 44% of patients, typically within about six weeks. The strongest predictors of this happening were a higher fluid pH, higher protein levels, and a steady decline in daily drainage volume.¹³

Combining the Two

Rather than choosing one approach over the other, some centers now combine them. In a randomized trial, talc was administered through an existing indwelling pleural catheter, and by day 35, successful pleurodesis was achieved in about 43% of those who received talc compared with 23% in a placebo group.¹⁴ No increase in catheter blockages or other complications was seen. A separate approach combining talc poudrage at thoracoscopy with simultaneous IPC placement has also shown promise, shortening hospital stays while boosting pleurodesis rates.¹⁵

Does Chemotherapy or Immunotherapy Control the Effusion on Its Own?

This is one of the more commonly misunderstood questions. You might assume that if the cancer responds well to systemic treatment, the effusion would resolve without needing a pleural procedure. The evidence suggests otherwise. In an observational analysis of prospectively collected data, researchers found no independent relationship between receiving systemic anticancer therapy and effusion resolution, even among tumors considered pharmacologically sensitive. The strongest predictor of effusion control was chemical pleurodesis, with an adjusted odds ratio of about 6.2, dwarfing the contribution of systemic therapy.¹⁶ The study’s conclusion was straightforward: patients with symptomatic effusions should receive early definitive pleural intervention regardless of the planned cancer treatment.

That said, a retrospective cohort study of lung cancers with high response rates to targeted or immune therapy found that early pleural intervention combined with systemic therapy led to significantly better effusion control (about 95% versus 59%) and longer overall survival compared with delayed pleural procedures.¹⁷ The takeaway is not that systemic therapy is useless for the effusion, but that it should not be used as a reason to defer dealing with the fluid. Treat the cancer and manage the pleural space at the same time.

When the Fluid Becomes Trapped or Loculated

Sometimes the effusion does not sit as a simple pool of free-flowing liquid. Fibrin strands and inflammatory debris can divide the fluid into separate pockets, a condition called loculation. Loculated effusions are harder to drain because a single tube or catheter cannot reach all the compartments. Several factors increase the risk of this happening: effusions associated with lung cancer, those that opacify the entire hemithorax on imaging, and effusions with a high ratio of fluid-to-blood LDH are all independent predictors of what is termed non-expandable lung, where the lung cannot fully re-inflate after drainage.¹⁸

For these complex cases, intrapleural fibrinolytic therapy can help. This involves instilling clot-dissolving drugs directly into the pleural space through a chest drain or IPC to break up the fibrin barriers and allow trapped fluid to flow out. A meta-analysis found that intrapleural fibrinolytic therapy was associated with significantly better respiratory improvement compared with standard drainage alone, with no meaningful increase in bleeding or other complications.¹⁹ Some centers have also used a combination of tissue plasminogen activator and an enzyme called dornase alfa (which breaks down DNA in the debris) through indwelling catheters, with reports of symptom resolution in multiloculated effusions that had resisted simpler approaches.²⁰

Complications of Indwelling Catheters

IPCs are generally well tolerated, but they are not without risks. A meta-analysis of complications found the following rates:

Infection: about 5.7% overall, making it the most common complication
Catheter problems: around 4.4%, including blockage, dislodgement, or malfunction
Pain: roughly 1.2%
Loculation: about 0.9%, where new pockets of fluid form around the catheter²¹

A less common but notable risk is catheter-tract metastasis, where tumor cells seed along the path the catheter takes through the chest wall. In a study of patients with IPCs, this occurred in about 10% of cases, with the vast majority being mesothelioma patients. It tended to appear late, at a median of roughly 280 days after insertion, and longer time with the catheter in place was the strongest risk factor.²² For mesothelioma specifically, some centers perform prophylactic radiotherapy to the insertion site to reduce this risk.

Cost Considerations

Because both IPCs and talc pleurodesis offer comparable symptom control, the choice between them often comes down to logistics and cost. Several economic analyses have examined this. The overall cost of managing patients with either approach tends to be similar, with one study finding mean costs of about $5,000 for IPCs and about $4,600 for talc pleurodesis, a difference that was not statistically significant.²³ The cost profile, however, shifts depending on how long the person survives. IPCs have lower upfront hospital costs but accumulate ongoing expenses for drainage supplies and nursing visits. For patients with a survival of fewer than about 14 weeks, IPCs appear clearly less costly because the ongoing supply expenses never have time to add up.²⁴ A separate cost-effectiveness analysis found that talc was less expensive under base-case assumptions, but that IPCs became the more cost-effective option when life expectancy dropped to about six weeks or less.²⁵ Prognostic scoring, then, is not just an academic exercise; it directly informs which treatment path makes the most financial and practical sense.

Using Pleural Fluid for Molecular Testing

One underappreciated benefit of draining a malignant pleural effusion is that the fluid itself can be a rich source of tumor DNA, sometimes even richer than a traditional tissue biopsy. For patients with lung adenocarcinoma in particular, identifying specific gene mutations like EGFR, ALK, or ROS1 is essential because these mutations can be targeted with specific drugs. A multicenter study of treatment-naive patients with stage IV lung adenocarcinoma found that standard testing of the cell pellet from pleural fluid identified driver mutations in about 51% of cases, while a broader cell-free DNA panel applied to the fluid’s supernatant detected them in about 64%. When all mutation types were considered, the broader panel identified at least one oncogenic alteration in over 92% of patients.²⁶

There are technical wrinkles, though. Cell-free DNA from pleural fluid comes in both short and long fragments, and the long fragments appear to contain genomic noise that can inflate certain measures used to assess whether immunotherapy might work, such as tumor mutational burden. Researchers have shown that the mutational burden calculated from unfiltered pleural fluid DNA was significantly higher than the actual tumor signal, suggesting that careful laboratory handling is needed to avoid misleading results.²⁷ As molecular testing of pleural fluid becomes more routine, these technical details will matter increasingly for treatment decisions.